

Supplementary Appendix

Table S1 List of immunosuppressant and cancer treatment drugs

Drug name	ATC code
Immunosuppressant drugs	
6-mercaptopurine	L01BB02
Abatacept	L04AA24
Adalimumab	L04AB04
Alemtuzumab	L04AA34
Anakinra	L04AC03
Apremilast	L04AA32
Azathioprine	L04AX01
Baricitinib	L04AA37
Basiliximab	L04AC02
Belatacept	L04AA28
Belimumab	L04AA26
Bendamustine	L01AA09
Brentuximab	L01FX05
Busulfan	L01AB01
Canakinumab	L04AC08
Certolizumab	L04AB05
Chlorambucil	L01AA02
Cyclophosphamide	L01AA01
Cyclosporine	L04AD01
Dacarbazine	L01AX04
Daclizumab	L04AC01
Dimethyl fumarate	L04AX07, N07XX09
Eculizumab	L04AA25
Elotuzumab	L01FX08
Estramustine	L01XX11
Etanercept	L04AB01
Everolimus	L04AA18, L01EG02, L01EG01
Fingolimod	L04AA27
Fotemustine	L01AD05
Glatiramer acetate	L03AX13
Golimumab	L04AB06
Ifosfamide	L01AA06

Infliximab	L04AB02
Ipilimumab	L01FX04
Ixekizumab	L04AC13
Leflunomide	L04AA13
Melphalan	L01AA03
Methotrexate	L01BA01, L04AX03
Mitoxantrone	L01DB07
Mycophenolate mofetil	L04AA06
Natalizumab	L04AA23
Obinutuzumab	L01FA03
Prednisone (≥20 mg for ≥14 days)	S01BA04, H02AB06, A07EA01, C05AA04, R01AD02, S01BA03
Rituximab	L01FA01
Secukinumab	L04AC10
Siltuximab	L04AC11
Sirolimus	L04AA10, S01XA23
Tacrolimus	L04AD02
Temozolomide	L01AX03
Teriflunomide	L04AA31
Thiotepa	L01AC01
Tocilizumab	L04AC07
Tofacitinib	L04AA29
Ustekinumab	L04AC05
Vedolizumab	L04AA33
Cancer treatment: radiotherapy drugs	
Radium dichloride	V10XX03
Cancer treatment: drugs	
Antineoplastic agents and immunomodulating agents	L01
Endocrine therapy	L02
Immunostimulants	L03

ATC=Anatomical Therapeutic Chemical.

Table S2 List of ICD-10 codes to identify immunocompromised patients and other comorbidities

ICD-10 codes	Description
HIV	
B20	Human immunodeficiency virus (HIV) disease
B97.35	Human immunodeficiency virus, type 2 (HIV-2)
Primary immune deficiency (disorders involving the immune mechanism)	
D50–D89	Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
K50	Crohn's disease (regional enteritis)
K51.90	Ulcerative enterocolitis
K52.9	Other and unspecified non-infectious gastroenteritis and colitis
L40	Psoriasis
M06.4	Rheumatoid arthritis and other inflammatory polyarthropathies
M32.9	Systemic lupus erythematosus
Q89.0, Q89.01	Asplenia (congenital)
Transplant	
T86	Complications of transplanted organs and tissue
Z94	Transplanted organ and tissue status
Solid tumours	
C00–C14	Malignant neoplasms of lip, oral cavity and pharynx
C15–C26	Malignant neoplasms of digestive organs
C30–C39	Malignant neoplasms of respiratory and intrathoracic organs
C40–C41	Malignant neoplasms of bone and articular cartilage
C43–C44	Melanoma and other malignant neoplasms of skin
C45–C49	Malignant neoplasms of mesothelial and soft tissue
C50	Malignant neoplasms of breast
C51–C58	Malignant neoplasms of female genital organs
C60–C63	Malignant neoplasms of male genital organs
C64–C68	Malignant neoplasms of urinary tract
C69–C72	Malignant neoplasms of eye, brain and other parts of central nervous system
C73–C75	Malignant neoplasms of thyroid and other endocrine glands
C76–C80	Malignant neoplasms of ill-defined, other secondary and unspecified sites
C7A	Malignant neuroendocrine tumours
C7B	Secondary neuroendocrine tumours
D00–D09	<i>In situ</i> neoplasms

D49	Neoplasms of unspecified behaviour
D37–D44	Neoplasms of uncertain behaviour
D48	Neoplasm of uncertain behaviour of other and unspecified sites
Haematological malignancies	
C81–C96	Malignant neoplasms of lymphoid, haematopoietic and related tissue
D45–D47	Polycythaemia vera, myelodysplastic syndromes and other neoplasms of uncertain behaviour of lymphoid, haematopoietic and related tissue
Sickle cell anaemia	
D57.0	Hb-SS disease with crisis
D57.1	Sickle cell disease without crisis
D57.2	Sickle cell/Hb-C disease
Major thalassaemia	
D56.0	Alpha thalassaemia
D56.1	Beta thalassaemia
Chronic kidney disease	
N17	Acute kidney failure
N18.4	CKD Stage 4
N18.5	CKD Stage 5
N18.6	ESRD
Z99.2	Dependence on renal dialysis
Z49	Encounter for other dialysis
Z49.01	Fitting and adjustment of extracorporeal dialysis catheter
Z49.02	Peritoneal dialysis
Z49.31	Encounter for adequacy testing for haemodialysis
Z49.32	Encounter for adequacy testing for peritoneal haemodialysis
Chronic liver disease	
I85.10	Oesophageal varices in diseases classified elsewhere, without mention of bleeding
K72.00	Acute and subacute necrosis of liver
K72.10	Other sequelae of chronic liver disease
K73	Chronic hepatitis, not elsewhere classified
K72.91	Hepatic encephalopathy
K73.9	Hepatitis, unspecified
K74	Fibrosis and cirrhosis of liver
K76.6	Portal hypertension
K76.7	Hepatorenal syndrome
K76.81	Hepatopulmonary syndrome

K76.89	Liver disorders
K76.9	Unspecified disorder of liver
K76.1	Chronic passive congestion of liver
R18.8	Other ascites
Type 1 or type 2 diabetes	
E08	Diabetes mellitus due to underlying condition
E09	Drug or chemical induced diabetes mellitus
E10	Type 1 diabetes mellitus
E11	Type 2 diabetes mellitus
E13	Other specified diabetes mellitus
Obesity	
E66.0	Obesity due to excess calories
E66.1	Drug-induced obesity
E66.2	Morbid (severe) obesity with alveolar hypoventilation
E66.8	Other obesity
E66.9	Obesity, unspecified
Chronic cardiovascular disease	
I20–I25	Ischaemic heart diseases
I27.0	Primary pulmonary hypertension
I27.2	Other secondary pulmonary hypertension
I27.81	Cor pulmonale (chronic)
I27.9	Pulmonary heart disease, unspecified
I5A	Non-ischaemic myocardial injury (nontraumatic)
I30–I52	Other forms of heart disease
Q20–Q28	Congenital malformations of the circulatory system
Chronic lung disease	
E84.9	Cystic fibrosis, unspecified
E84.11	Meconium ileus in cystic fibrosis
I26	Pulmonary embolism
E84.0	Cystic fibrosis with pulmonary manifestations
I27.82	Chronic pulmonary embolism
J44.9	Chronic obstructive pulmonary disease
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J84.10	Pulmonary fibrosis, unspecified
J84.89	Other specified interstitial pulmonary diseases
J98.4	Other disorders of lung
Chronic neurological disease	
A81.01	Variant Creutzfeldt–Jakob disease

F01.50	Vascular dementia without behavioural disturbance
F07.0	Personality change due to known physiological condition
G10	Huntington's disease
G20	Parkinson's disease
G21	Secondary parkinsonism
G23	Other degenerative diseases of basal ganglia
G24	Dystonia
G25	Other extrapyramidal and movement disorders
G26	Extrapyramidal and movement disorders in diseases classified elsewhere
G30	Alzheimer's disease
G31	Other degenerative diseases of nervous system, not elsewhere classified
G32	Other degenerative disorders of nervous system in diseases classified elsewhere
I60	Nontraumatic subarachnoid haemorrhage
I61	Nontraumatic intracerebral haemorrhage
I62	Other and unspecified nontraumatic intracranial haemorrhage
I63	Cerebral infarction
I65	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction
I66	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction
I67	Other cerebrovascular diseases
I68	Cerebrovascular disorders in diseases classified elsewhere
I69	Sequelae of cerebrovascular disease
R47.01	Aphasia
R40.20	Unspecified coma
Cancer treatment: radiotherapy or chemotherapy	
Z51.0	Encounter for antineoplastic radiation therapy
Z51.1	Encounter for antineoplastic chemotherapy and immunotherapy
COVID-19-related hospitalizations	
B34.2	Coronavirus infection, unspecified
U07.1	COVID-19
B97.2	Coronavirus as the cause of diseases classified elsewhere

CKD=chronic kidney disease, COVID-19=coronavirus disease 2019, ESRD=end-stage renal disease, HIV=human immunodeficiency virus, ICD-10=International Classification of Disease version 10

Table S3 List of ICD-10 procedure codes

ICD-10 codes	Description
Invasive mechanical ventilation	
0BH13EZ	Insertion of endotracheal airway into trachea, percutaneous approach
0BH17EZ	Insertion of endotracheal airway into trachea, via natural or artificial opening
0BH18EZ	Insertion of endotracheal airway into trachea, via natural or artificial opening
0B110F4	Bypass trachea to cutaneous with tracheostomy device, open approach
0B110Z4	Bypass trachea to cutaneous, open approach
0B113F4	Bypass trachea to cutaneous with tracheostomy device, percutaneous approach
0B113Z4	Bypass trachea to cutaneous, percutaneous approach
0B114F4	Bypass trachea to cutaneous with tracheostomy device, percutaneous endoscopic approach
0B114Z4	Bypass trachea to cutaneous, percutaneous endoscopic approach
5A1.935Z	Extracorporeal or systemic assistance and performance, physiological systems, performance, respiratory, less than 24 consecutive hours, ventilation, no qualifier
5A1.945Z	Extracorporeal or systemic assistance and performance, physiological systems, performance, respiratory, 24–96 consecutive hours, ventilation, no qualifier
5A1.955Z	Extracorporeal or systemic assistance and performance, physiological systems, performance, respiratory, greater than 96 consecutive hours, ventilation, no qualifier
Non-invasive ventilation	
5A0.9357	Assistance with respiratory ventilation, less than 24 consecutive hours, continuous positive airway pressure
5A0.9358	Assistance with respiratory ventilation, less than 24 consecutive hours, intermittent positive airway pressure
5A0.9359	Assistance with respiratory ventilation, less than 24 consecutive hours, continuous negative airway pressure
5A0.935B	Assistance with respiratory ventilation, less than 24 consecutive hours, intermittent negative airway pressure
5A0.935Z	Assistance with respiratory ventilation, less than 24 consecutive hours

5A0.9457	Assistance with respiratory ventilation, 24–96 consecutive hours, continuous positive airway pressure
5A0.9458	Assistance with respiratory ventilation, 24–96 consecutive hours, intermittent positive airway pressure
5A0.9459	Assistance with respiratory ventilation, 24–96 consecutive hours, continuous negative airway pressure
5A0.945B	Assistance with respiratory ventilation, 24–96 consecutive hours, intermittent negative airway pressure
5A0.945Z	Assistance with respiratory ventilation, 24–96 consecutive hours
5A0.9557	Assistance with respiratory ventilation, greater than 96 consecutive hours, continuous positive airway pressure
5A0.9558	Assistance with respiratory ventilation, greater than 96 consecutive hours, intermittent positive airway pressure
5A0.9559	Assistance with respiratory ventilation, greater than 96 consecutive hours, continuous negative airway pressure
5A0.955B	Assistance with respiratory ventilation, greater than 96 consecutive hours, intermittent negative airway pressure
5A0.955Z	Assistance with respiratory ventilation, greater than 96 consecutive hours
5A1.9054	Respiratory ventilation, dingle, nonmechanical
Z99.11	Dependence on respirator (ventilator) status

ICD-10=International Classification of Disease version 10

Table S4 Acute period (29-day) all-cause and COVID-19-related outcomes by study month

Outcome	Study month									
	Overall	Nov 2021	Dec 2021	Jan 2022	Feb 2022	Mar 2022	Apr 2022	May 2022	Jun 2022	Jul 2022
Number of patients treated with sotrovimab	634	20	44	178	112	148	127	1	2	2
Hospitalized due to any cause, <i>n</i> (%)	79 (12.5)	4 (20.0)	10 (22.7)	20 (11.2)	9 (8.0)	22 (14.9)	14 (11.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hospitalized due to COVID-19, <i>n</i> (%)	16 (2.5)	0 (0.0)	4 (9.1)	2 (1.1)	3 (2.7)	4 (2.7)	3 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)
Hospitalized due to unknown reason, <i>n</i> (%)	7 (1.1)	0 (0.0)	1 (2.3)	5 (2.8)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Died due to any cause, <i>n</i> (%)	7 (1.1)	0 (0.0)	1 (2.3)	2 (1.1)	2 (1.8)	2 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

COVID-19=coronavirus disease 2019